Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BRD3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BRD3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BRD3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/BRD3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/BRD3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BRD3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BRD3 | deletion | Frame_Shift_Del | rs763134487 | c.71delN | p.Pro24ArgfsTer24 | p.P24Rfs*24 | Q15059 | protein_coding | | | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR |
BRD3 | SNV | Missense_Mutation | rs768187282 | c.1021N>A | p.Glu341Lys | p.E341K | Q15059 | protein_coding | tolerated(0.31) | benign(0.328) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | | c.1417N>A | p.Val473Met | p.V473M | Q15059 | protein_coding | tolerated(0.08) | benign(0.108) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | rs200522998 | c.1967N>T | p.Ser656Leu | p.S656L | Q15059 | protein_coding | deleterious(0.04) | possibly_damaging(0.874) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | | c.1122N>T | p.Gln374His | p.Q374H | Q15059 | protein_coding | tolerated(0.06) | possibly_damaging(0.746) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | | c.1781N>A | p.Arg594Gln | p.R594Q | Q15059 | protein_coding | deleterious(0.02) | benign(0.319) | TCGA-AP-A0LN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | rs775918544 | c.1117G>A | p.Ala373Thr | p.A373T | Q15059 | protein_coding | tolerated(0.11) | probably_damaging(0.935) | TCGA-AP-A0LP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Hormone Therapy | megace | SD |
BRD3 | SNV | Missense_Mutation | rs141557823 | c.1343N>T | p.Ser448Leu | p.S448L | Q15059 | protein_coding | deleterious(0.03) | benign(0.236) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
BRD3 | SNV | Missense_Mutation | rs760534944 | c.589N>A | p.Ala197Thr | p.A197T | Q15059 | protein_coding | tolerated(0.45) | benign(0.102) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | novel | c.2011N>T | p.Arg671Cys | p.R671C | Q15059 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | ABBV-744 | ABBV-744 | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | ALPRAZOLAM | ALPRAZOLAM | 22137933 |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | PMID26924192-Compound-102 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | ESTAZOLAM | ESTAZOLAM | 22137933 |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | inhibitor | 252827533 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | PMID26924192-Compound-104 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | Pyrrolo-pyrrolone derivative 1 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | inhibitor | 187051822 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | L-655708 | CHEMBL52030 | 22137933 |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | inhibitor | 404859011 | | |